Quick Answer
The current EGRIFTA SV label lists a tesamorelin dose of 1.4 mg injected subcutaneously once daily. The major clinical studies behind tesamorelin commonly used 2 mg once daily with the older 1 mg-vial formulation, and the DailyMed label explains that systemic exposure is similar between the 1.4 mg EGRIFTA SV dose and the older 2 mg EGRIFTA dose.
For research peptides, dosage questions often mix two different topics: evidence-based dosing and vial math. Evidence-based dosing comes from labels and trials. Vial math is about concentration after reconstitution and syringe units. Those should stay separate.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileThe Current Label Dose
DailyMed's current EGRIFTA SV prescribing information lists 1.4 mg, equal to 0.35 mL of the reconstituted solution, injected subcutaneously once daily. The label also says EGRIFTA SV is injected into the abdomen and that injection sites should be rotated.
That label language is useful because it answers the most common tesamorelin dosage question with a real source. It also prevents confusion between different tesamorelin formulations. EGRIFTA SV uses a 2 mg vial formulation, while older EGRIFTA references and studies often discuss a 2 mg daily dose with a different formulation.
| Context | Dose language |
|---|---|
| EGRIFTA SV label | 1.4 mg once daily, 0.35 mL after reconstitution. |
| Older EGRIFTA clinical-trial context | 2 mg subcutaneously once daily in major studies. |
| Formulation note | The label says the 1.4 mg EGRIFTA SV exposure is similar to the older 2 mg EGRIFTA exposure. |
| Research vial math | Depends on vial amount, added liquid, final concentration, and syringe units. |
Why 1.4 Mg And 2 Mg Both Appear Online
The 1.4 mg versus 2 mg confusion is understandable. Many tesamorelin studies used 2 mg daily. The current EGRIFTA SV label lists 1.4 mg daily. The reason both appear is formulation-specific.
The EGRIFTA SV label states that the dosage recommendations apply to the 2 mg-per-vial SV formulation and that it differs from the older 1 mg-per-vial formulation. It also states that systemic exposure is similar between the 1.4 mg SV dose and the older 2 mg EGRIFTA dose.
So the useful reader takeaway is not "one number is always right and the other is wrong." It is that dosage language must be tied to the product formulation and source.
What Clinical Trials Studied
The best-known randomized trial studied tesamorelin 2 mg subcutaneously once daily in adults with HIV and central fat accumulation. At six months, visceral adipose tissue fell by 10.9% in the tesamorelin group compared with 0.6% with placebo. In the safety extension, people who continued tesamorelin had about an 18% VAT reduction over 12 months.
Those studies are why dosage matters. Tesamorelin's reputation is built on a daily protocol in controlled clinical settings, not occasional or loosely defined use. When someone discusses tesamorelin dosing protocol, the credible starting point is the studied daily clinical structure.
Dosage Per Day
Tesamorelin is typically discussed as a once-daily peptide in both label and clinical-study contexts. That separates it from weekly incretin drugs and from some peptide protocols that use intermittent schedules.
The once-daily pattern also changes how people think about vial supply, cost, and reconstitution math. A small difference in daily amount can make a large difference over a month. That is why calculator math can be useful for research planning, even though it is not a substitute for medical dosing.
Use the peptide calculatorCalculate concentration and syringe-unit math for research planning.Open calculatorMen, Women, And Bodybuilding Context
It is common to see tesamorelin dosage discussed differently for men, women, and bodybuilding, but the highest-quality sources do not provide separate casual protocols for those categories. The label dose is not split by sex. The published trial protocols are defined by study population and eligibility criteria, not by gym goals.
That does not make the questions invalid. It means the answer should be grounded. Tesamorelin's best-supported use case is visceral abdominal fat reduction in a specific clinical population. Body-composition interest is understandable, but it should not be treated as the same thing as a prescribing protocol.
Dosage Versus Reconstitution Math
A 5 mg or 10 mg tesamorelin vial is a total amount in a vial. It is not automatically a daily dose. Once liquid is added, the concentration changes based on how much liquid was used. Syringe-unit math then depends on the final concentration and the amount being measured.
For example, adding more liquid lowers concentration per unit of volume. Adding less liquid raises concentration per unit of volume. The vial amount has not changed, but the measurement changes. That is why a calculator is better than mental math for research planning.
After The Dosage Question
Once the dosage evidence is clear, product comparison becomes a separate issue. A vendor table can help compare research listings, but it should not be read as a dosing guide. Its job is to show product and vendor signals, not to decide a protocol.
Tesamorelin Research Vendors
View all Tesamorelin vendors| Vendor | Country | Rating | COAs | Promo | Payment | Shipping | Website |
|---|---|---|---|---|---|---|---|
| LA Peptides | USA | 5.0 (1) | Yes | 10% off (AMINORANK) | Card, ACH | Fast shipping, International | Buy |
| NextGenPeps | USA | 5.0 (1) | Yes | 10% off (AMINORANK) | Card, ACH, Crypto | Fast shipping | Buy |
| Alpha Peptides | USA | 0.0 (0) | Yes | 10% off (AMINORANK) | Card | Standard | Buy |
| Ascension Peptides | USA | 0.0 (0) | Yes | 50% off (AMINORANK) | Card | Standard | Buy |
| BioCollex | USA | 0.0 (0) | Yes | 10% off (AMINORANK) | Not listed | International | Buy |
| Coastal Peptides | USA | 0.0 (0) | Yes | None listed | Card | Fast shipping, International | Buy |
FAQ
Is tesamorelin 1.4 mg or 2 mg?
Both numbers appear because of formulation context. The current EGRIFTA SV label lists 1.4 mg once daily, while major studies with the older formulation used 2 mg once daily.
How often is tesamorelin taken in studies?
The major clinical studies used daily subcutaneous tesamorelin.
Is a 10 mg vial a 10 mg dose?
No. A 10 mg vial describes the total vial amount. Dose, concentration, liquid volume, and syringe units are separate concepts.
What is the safest way to understand tesamorelin dosage?
Use labels and clinical studies for dose context, and use a calculator only for concentration and measurement math.